Dedicated vs. Multi-Product Facilities: Navigating FDA & EMA Compliance

Are you prepared for the "one question" that can shut down your multi-product pharma campaign? Learn how to scientifically justify shared equipment and avoid costly FDA 483s or EMA non-compliance findings.

In the world of pharmaceutical manufacturing, the debate between Dedicated vs. Multi-Product facilities is more than an operational choice—it’s a commitment to patient safety. As global regulators move away from arbitrary limits like 10ppm toward a holistic Quality Risk Management (QRM) approach guided by ICH Q9, your justification must be bulletproof.
​In this video, we break down:
​The Regulatory Shift: Why the "Old Way" no longer satisfies FDA and EMA auditors.
​The 3 Pillars of Potency: A deep dive into Toxicological Data (PDE), Product Solubility, and Equipment Design.
​The Bracketing Strategy: How to identify your "Worst-Case Monster" to streamline validation without sacrificing safety.
​The Golden Nugget: Understanding EU GMP Annex 15 and when dedicated equipment becomes mandatory.

​[Call to Action]
If you found this breakdown helpful, please Like, Subscribe, and hit the notification bell for more deep dives into Pharma QA and Compliance!

​[Timestamps]
0:00 The Audit Question That Stops Everything
0:50 The Core Conflict: Safety vs. Efficiency
1:31 Dedicated vs. Multi-Product Trade-offs
2:12 The 3 Pillars of Potency
4:12 Expert Strategy: Worst-Case Bracketing
5:29 The Ultimate Compliance Safety Net

​#PharmaceuticalManufacturing #FDACompliance #EMAGMP #QualityAssurance #ICHQ9 #PharmaAudit #GMPAnnex15 #TheIndianPharmacist #ValidationStrategy #QualityRiskManagement

Видео Dedicated vs. Multi-Product Facilities: Navigating FDA & EMA Compliance канала The Indian Pharmacist | Global Compliance & QA